Letko, Brosseau & Associates’s AstraZeneca AZN Stock Holding History

Letko, Brosseau & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-518,105	Closed	-$37M	–	99
2014 Q3	$37M	Sell	518,105 -77,171	-13%	-$5.65M	0.31%	64
2014 Q2	$44.2M	Sell	595,276 -1,413,840	-70%	-$102M	0.35%	62
2014 Q1	$130M	Sell	2,009,116 -967,303	-32%	-$62.5M	1.11%	41
2013 Q4	$177M	Sell	2,976,419 -98,855	-3%	-$5.37M	1.46%	30
2013 Q3	$160M	Buy	3,075,274 +39,435	+1%	+$1.98M	1.39%	33
2013 Q2	$144M	Buy	+3,035,839	New	+$155M	1.35%	34

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Letko, Brosseau & Associates's AZN Position: Q4 2014 in Review

Letko, Brosseau & Associates sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 518,105 shares — an estimated $37M sold.

Letko, Brosseau & Associates first reported a position in AZN in Q2 2013 and held it in 6 quarters. The position peaked at $177M in Q4 2013. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

Letko, Brosseau & Associates reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
Letko, Brosseau & Associates sold 518,105 AstraZeneca shares in Q4 2014, an estimated $37M.
Letko, Brosseau & Associates first reported a position in AstraZeneca in Q2 2013 and held it in 6 quarters.
Letko, Brosseau & Associates's AstraZeneca position peaked at $177M in Q4 2013.
404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2014, filed 10 Feb 2015.